Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages

Glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-dependent glucose transporter 2 inhibitor (SGLT2i), in addition to lowering glucose, have pleiotropic effects on the heart, kidneys, and liver. These drugs have thus come into widespread use for treating type 2 diabetes (T2DM). However, m...

Full description

Bibliographic Details
Main Authors:	Masao Koike, Hitoki Saito, Genta Kohno, Masahiro Takubo, Kentaro Watanabe, Hisamitsu Ishihara
Format:	Article
Language:	English
Published:	MDPI AG 2021-10-01
Series:	International Journal of Molecular Sciences
Subjects:	type 2 diabetes mellitus GLP-1 receptor agonists SGLT2 inhibitors pancreatic β-cells fatty liver
Online Access:	https://www.mdpi.com/1422-0067/22/21/11463

Similar Items

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
by: Marvin Wei Jie Chua
Published: (2021-12-01)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
by: Martina Belli, et al.
Published: (2022-11-01)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Heeyoung Lee, et al.
Published: (2021-09-01)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
by: Lixin Du, et al.
Published: (2022-11-01)

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
by: Dion R. P. Muller, et al.
Published: (2023-10-01)

Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
by: Angelica Cersosimo, et al.
Published: (2024-03-01)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
by: Bartosz Rolek, et al.
Published: (2023-07-01)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
by: Katarzyna Wołos-Kłosowicz, et al.
Published: (2022-10-01)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023-03-01)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
by: Lixin Du, et al.
Published: (2022-08-01)

GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
by: Raffaele Marfella, et al.
Published: (2024-01-01)

Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
by: André J. Scheen
Published: (2024-01-01)

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
by: Yaofu Zhang, et al.
Published: (2022-11-01)

Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
by: Yunpeng Gu, et al.
Published: (2023-03-01)

Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system
by: Sarina Gadgaard, et al.
Published: (2023-04-01)

GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
by: Alessio Mazzieri, et al.
Published: (2023-11-01)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
by: Magdalena Złotek, et al.
Published: (2023-11-01)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
by: Panagiotis I. Georgianos, et al.
Published: (2022-02-01)

Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors
by: Cosmin Mihai Vesa, et al.
Published: (2020-05-01)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
by: Chudleigh RA, et al.
Published: (2020-02-01)

Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
by: Almudena Castro Conde, et al.
Published: (2023-06-01)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
by: Qiao Q, et al.
Published: (2016-06-01)

Vergleich der Gesundheitskosten von Typ-2 Diabetikern bei der Anwendung von Empagliflozin, DPP-4-Hemmern und GLP-1-Agonisten
by: Prof. Dr. rer. oec. Thomas Wilke, et al.
Published: (2022-12-01)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
by: Qian Zhou, et al.
Published: (2023-10-01)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)

Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
by: Yi-lin Huang, et al.
Published: (2023-06-01)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
by: Hisayuki Katsuyama, et al.
Published: (2023-03-01)

Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
by: Katharina Luise Hupa-Breier, et al.
Published: (2021-03-01)

Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD)
by: André J. Scheen
Published: (2023-07-01)

Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients in real life
by: Ramón Baeza-Trinidad, et al.
Published: (2023-07-01)

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
by: Riccardo Nevola, et al.
Published: (2023-01-01)

GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
by: Kallirhoe Kalinderi, et al.
Published: (2024-03-01)

Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents
by: Diego García-Compeán, et al.
Published: (2023-07-01)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
by: Amisha Wallia, et al.
Published: (2023-05-01)

Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists
by: Pei Shang, et al.
Published: (2021-09-01)

Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study
by: Chih-Yiu Tsai, et al.
Published: (2022-01-01)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
by: Jennifer Matthews, et al.
Published: (2023-09-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

Editorial: Pharmacology and treatment methods for NAFLD in the context of diabetes
by: Mohamed Abu-Farha, et al.
Published: (2022-09-01)

The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia
by: Ghada M. A. Ajabnoor, et al.
Published: (2023-03-01)